Market closedNon-fractional
Zymeworks/ZYME
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Zymeworks
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Ticker
ZYME
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Middletown, United States
Employees
275
Website
www.zymeworks.com
Zymeworks Metrics
BasicAdvanced
$758M
Market cap
-
P/E ratio
-$1.77
EPS
1.15
Beta
-
Dividend rate
Price and volume
Market cap
$758M
Beta
1.15
Financial strength
Current ratio
6.922
Quick ratio
6.609
Long term debt to equity
4.81
Total debt to equity
5.764
Management effectiveness
Return on assets (TTM)
-16.09%
Return on equity (TTM)
-27.64%
Valuation
Price to revenue (TTM)
15.005
Price to book
1.72
Price to tangible book (TTM)
1.8
Price to free cash flow (TTM)
-9.818
Growth
Revenue change (TTM)
-88.69%
Earnings per share change (TTM)
-168.34%
3-year revenue growth (CAGR)
17.23%
3-year earnings per share growth (CAGR)
-22.51%
What the Analysts think about Zymeworks
Analyst Ratings
Majority rating from 8 analysts.
Zymeworks Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$10M
-40.83%
Net income
-$32M
119.44%
Profit margin
-316.00%
270.89%
Zymeworks Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.76
-$0.41
-$0.20
-$0.42
-
Expected
-$0.47
-$0.47
-$0.43
-$0.29
-$0.20
Surprise
61.55%
-12.65%
-53.89%
44.83%
-
Zymeworks News
AllArticlesVideos
Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer
GlobeNewsWire·1 day ago
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate
GlobeNewsWire·5 days ago
Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Zymeworks stock?
Zymeworks (ZYME) has a market cap of $758M as of July 26, 2024.
What is the P/E ratio for Zymeworks stock?
The price to earnings (P/E) ratio for Zymeworks (ZYME) stock is 0 as of July 26, 2024.
Does Zymeworks stock pay dividends?
No, Zymeworks (ZYME) stock does not pay dividends to its shareholders as of July 26, 2024.
When is the next Zymeworks dividend payment date?
Zymeworks (ZYME) stock does not pay dividends to its shareholders.
What is the beta indicator for Zymeworks?
Zymeworks (ZYME) has a beta rating of 1.15. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Zymeworks stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.